The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,314.00
Bid: 12,314.00
Ask: 12,316.00
Change: -90.00 (-0.73%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Homebuilders knocked lower by remarks from Carney

Tue, 14th Jul 2015 13:09

(ShareCast News) - Bank of England Governor Mark Carney told the Treasury Select Committee Bank Rate may be headed higher a little bit sooner than markets anticipated, sending stocks - especially homebuilders - listed on the second tier index promptly lower.As of 12:13 the top flight index was off by 19.22 points to 6,718.36 and the FTSE 250 lower by a hefty 141.80 points to 17,567.33.In testimony to the Committee Carney said that, "the point at which interest rates may begin to rise is moving closer given the performance of the economy."That sent the yield on the benchmark 10-year Gilt higher by four basis points to 2.15% and saw the pound snap higher towards 1.56 versus the US dollar."We judge these comments as supporting our view that the Bank is likely to deliver the first rate hike earlier than the current market pricing of May 2016. Our forecast is for a February 2016 move," economists at BNP Paribas said in a research report e-mailed to clients.Subdued core inflation in the UKHis remarks came after the latest CPI figures from ONS revealed that core inflation in the UK slipped a tad in June, to a 0.8% year-on-year pace after a reading of 0.9% in May - the joint lowest print since March 2001.Nevertheless, "this weakness continues to largely reflect cheaper goods imports. Inflation in the services sector, while below its average of 3.5% over the last decade, was a much stronger 2.2%," Samuel Tombs, Senior UK economist at Capital Economics pointed out.The headline consumer price index was flat versus a year ago, after a rise of just 0.1% in May, as expected by economists."We believe it is most likely that consumer price inflation will hover around zero through the summer and then start heading gradually but decisively up from September. There is obviously the risk that there could be another very brief dip into deflation if oil prices extend their current softening," Dr.Howard Archer, chief UK+European economist at IHS Global Insight explained to clients.All eyes on AthensActing as a backdrop, all eyes were on the parliament in Athens and whether it approve the list of reforms asked of it by creditors.That came amid an urgent need for fresh funds by Greece to meet a 20 July payment of €3.5bn falling due to the European Central Bank and to recapitalise the country's banks and restore the flow of credit in the economy."Capital control implementation can be swift, but its full removal is a lengthy process," Goldman Sachs told clients, adding that a normally functioning banking sector could be expected immediately.Defence sector finds a bidShares in defence and aerospace engineer Meggitt rose on Tuesday following a report in the Financial Times that a merger with Cobham might be on the cards. Atif Latif, director of trading at Guardian Stockbrokers, said he sees the rationale of a tie-up between the two as a defence play.Analysts at Deutsche Bank upgraded their rating for Sky from 'hold' to 'buy' and raised estimates for 2017 by 20% more than consensus. In a note to clients, Deutsche Bank said the FTSE 250 firm was the best positioned in Europe to capitalise on growth areas related to online video.Shares in homebuilders such as Taylor Wimpey, Barratt Developments and Persimmon were all knocked lower by Carney's remarks.AstraZeneca's Iressa drug, which is used in the treatment of metastatic non-small cell lung cancer (NSCLC), has been approved by the US Food and Drug Administration.Iressa is approved in 91 countries for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive NSCLC, which is the most common type of lung cancer.Miner BHP Billiton reported that director Sir John Buchanan died on Monday, having served on the board from 2003 up until the time of his death. Buchanan, who was the senior independent director of Anglo-Australian giant, "provided wise counsel to his fellow directors and to management, and made an invaluable contribution to BHP Billiton," said chairman Jac Nasser.Market MoverstechMARK 3,173.01 -0.20%FTSE 100 6,717.31 -0.31%FTSE 250 17,563.25 -0.82%FTSE 100 - RisersSky (SKY) 1,113.00p +3.25%Meggitt (MGGT) 478.40p +1.68%Reed Elsevier (REL) 1,095.00p +0.92%International Consolidated Airlines Group SA (CDI) (IAG) 553.50p +0.82%Unilever (ULVR) 2,904.00p +0.80%British American Tobacco (BATS) 3,642.00p +0.69%Carnival (CCL) 3,494.00p +0.60%Lloyds Banking Group (LLOY) 85.76p +0.54%Morrison (Wm) Supermarkets (MRW) 178.80p +0.45%Hikma Pharmaceuticals (HIK) 2,073.00p +0.34%FTSE 100 - FallersTaylor Wimpey (TW.) 185.80p -3.18%Barratt Developments (BDEV) 624.00p -2.73%Persimmon (PSN) 1,967.00p -2.33%Weir Group (WEIR) 1,587.00p -2.22%GKN (GKN) 317.70p -2.10%TUI AG Reg Shs (DI) (TUI) 1,066.00p -1.93%Aberdeen Asset Management (ADN) 401.30p -1.91%Johnson Matthey (JMAT) 3,003.00p -1.54%Pearson (PSON) 1,231.00p -1.52%Marks & Spencer Group (MKS) 539.50p -1.46%FTSE 250 - RisersInternational Personal Finance (IPF) 363.30p +3.03%Evraz (EVR) 121.00p +2.89%Centamin (DI) (CEY) 59.90p +1.53%AO World (AO.) 133.20p +1.52%Greggs (GRG) 1,146.00p +1.42%NMC Health (NMC) 810.50p +1.31%Carillion (CLLN) 356.30p +1.31%Pace (PIC) 372.00p +1.20%Laird (LRD) 365.10p +1.11%Telecom Plus (TEP) 1,055.00p +1.05%FTSE 250 - FallersDrax Group (DRX) 248.50p -5.08%Tullow Oil (TLW) 288.80p -4.47%Hiscox Limited (CDI) (HSX) 869.00p -3.87%Man Group (EMG) 151.70p -3.80%Bellway (BWY) 2,304.00p -3.52%Hunting (HTG) 518.50p -3.36%Bovis Homes Group (BVS) 1,116.00p -3.21%Berkeley Group Holdings (The) (BKG) 3,258.00p -2.78%Just Retirement Group (JRG) 173.10p -2.75%Paragon Group Of Companies (PAG) 384.10p -2.61%
More News
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more
19 Feb 2024 08:36

TOP NEWS: AstraZeneca celebrates Tagrisso approval and new data

(Alliance News) - AstraZeneca PLC on Monday announced new study data and a new approval for its cancer medication Tagrisso.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.